2025.02.13Restore Vision, one of Remiges' portfolio companies, announced the first patient dosed in Phase I/II clinical trial of RV-001 for gene-agnostic retinitis pigmentosa

2025.02.06InFlectis BioScience, one of our portfolio companies, announced today promising Phase 2a clinical study results for IFB-088 in patients with bulbar-onset ALS

2024.10.24KisoJi Biotechnology, one of Remiges' portfolio companies, has entered a strategic collaboration agreement with Cancer Research UK on KisoJi's unique single-domain antibody program, KJ-103 targeting TROP2 for the treatment of solid tumors

2024.10.08Qinotto, one of Remiges' portfolio companies, has entered a research collaboration and license agreement with Lilly on a novel shuttle program for delivering novel agents beyond blood-brain barrier for the treatment of neurodegenerative diseases

2024.09.26OMEICOS, a portfolio company of Remiges Ventures, completes enrollment of PMD-OPTION study in primary mitochondrial disease

　　News　＞　

What Remiges Does >

Team >

Portfolio Companies >

Contact >

LP Portal >